The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|March 6, 2020
- Pharmaceutical Technology's In the Lab eNewsletter-04-01-2020
- Volume 15
- Issue 4
Nexelis to Acquire ImmunXperts, an Immunogenicity and Immune-Oncology Testing Lab
The acquisition will expand Nexelis’ immunology testing expertise.
Advertisement
On March 4, 2020, Nexelis, a portfolio company of Ampersand Capital Partners and a provider of assay development and advanced laboratory testing, announced that it has signed a definitive agreement to acquire ImmunXperts, a Brussels, Belgium-based immunogenicity and immune-oncology testing laboratory. The transaction is expected to close by the end of March. Financial details of the deal were not disclosed.
ImmunXperts has developed and performs a full offering of immunogenicity and immuno-oncology in-vitro functional and potency assays, which help pharmaceutical and biotech sponsors screen, select, and optimize lead compounds before the initiation of in-vivo trials.
“ImmunXperts’ immunology testing expertise will help Nexelis more broadly serve the needs of our customers,” said Benoit Bouche, Nexelis president and CEO, in a company press release. “Nexelis will now have an unrivaled ability to efficiently develop immunogenicity assays, qualify and validate them in a regulated environment, and then ultimately perform them utilizing our high-throughput platforms in support of clinical trials.”
“We are proud of ImmunXperts’ achievements over the past five years and are grateful for the support obtained from our investors and partners, our employees, and the Wallonia region. We are excited to continue our growth trajectory as part of Nexelis and serve as a European hub for the company,” added Sofie Pattijn, chief technology officer, and Thibault Jonckheere, CEO, ImmunXperts, in the press release. Both Pattijn and Jonckheere will continue in senior leadership roles at Nexelis.
Source:
Articles in this issue
over 6 years ago
trinamiX Launches a Mobile NIR Spectroscopy Solutionover 6 years ago
Asymmetrex’s New Algorithms Offer Low Cost Rapid Cell Countingover 6 years ago
Integra Now Offers New High-Volume Pipettesover 6 years ago
Trianni in License Agreement with Nkarta for Trianni Mouseover 6 years ago
Thermo Fisher Scientific to Acquire Qiagen for $11.5 BillionAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement